Morgan Stanley Just Named Affirm Its Top Pick: Private Credit Fears Are Overdone and a May Catalyst Could Be Huge

Morgan Stanley named Affirm Holdings a Top Pick with an Overweight rating and a $76 price target, citing upside estimate revisions, easing private credit fears, and a May 12 Investor Forum catalyst. Operationally, Q2 FY2026 revenue rose 30% to $1.123 billion, GMV increased 36% to $13.8 billion, and operating income jumped 2,821% to $117.6 million, while funding costs fell from 7% in Q3 FY2025 to 6% in Q2 FY2026. The key watch items are whether Affirm raises GMV, margin, and EPS targets at the forum and whether delinquencies and partner concentration remain contained.

Analysis

The setup is less about one analyst call and more about a potential regime shift in how AFRM is financed and valued. If Morgan Stanley is right that funding-risk fears are overstated, the market is likely underappreciating the operating leverage embedded in a lower-cost capital stack: every incremental basis point of funding relief should flow disproportionately into take rate durability and EPS revisions, not just headline growth.

The near-term catalyst is asymmetric because management has a history of using investor events to reset the goalposts. A May forum that lifts GMV, margin, and EPS targets would likely compress the multiple gap between AFRM and other consumer-finance compounders, especially if the market interprets revised guidance as proof that growth and credit quality can coexist. The second-order winner could be the broader BNPL complex if AFRM proves the funding model is stable; the loser is any short thesis built on capital-market dependence rather than loan performance.

The main risk is that the stock is being carried by narrative ahead of data. Delinquencies tied to specific cohorts and partner concentration are the kinds of issues that can look manageable until growth slows, and then they become the first variable investors question. If the forum disappoints or management avoids meaningful target raises, the unwind could be sharp because positioning is likely crowded around the same catalyst window.

Contrarianly, the market may already be partially pricing in the "no funding problem" argument, but not the size of the rerating if targets move higher. The cleaner trade is not a blind long into the event; it is a catalyst-driven structure with defined downside, because the gap between "private credit fears are exaggerated" and "guidance gets raised" is where the edge lives.

Key Decisions for Investors

• Buy AFRM common or call spreads into the May 12 investor forum with a 2-6 week horizon; upside is a rerating on any target raise, downside is limited if the event is merely confirmatory, but expect elevated volatility into the print.
• Structure a bullish risk-reversal in AFRM for the event window: finance upside with out-of-the-money put sale only if you are comfortable owning through a post-event drawdown; this expresses conviction that the funding overhang is mispriced.
• Pair long AFRM vs. short a BNPL or consumer-finance peer basket over the next 1-3 months; the relative trade captures a potential guide-up / multiple expansion in AFRM while dampening sector beta.
• Trim or avoid outright short exposure in AFRM until after the forum; the risk/reward is unfavorable for shorts because a guidance increase would force immediate estimate revision and likely squeeze crowded positioning.
• If AFRM rallies hard on the event but fails to expand margins or improve credit commentary, use that strength to fade into earnings quality concerns rather than chase the move.